Phase II Randomized Study of Fianlimab Plus Cemiplimab Versus Cemiplimab Plus Placebo in First-Line Treatment of Participants With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Is Positive for PD-L1 Expression
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Cemiplimab (Primary) ; Fianlimab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 16 Jan 2025 New trial record